Trending NewsTrending NewsNYSE:CC Chemours (CC) Stock Price, News & Analysis $21.47 -0.80 (-3.58%) Closing price 03:59 PM EasternExtended Trading$21.55 +0.08 (+0.36%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Chemours Stock (NYSE:CC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Chemours alerts:Sign Up Key Stats Today's Range$20.42▼$22.3150-Day Range$17.60▼$27.9352-Week Range$9.13▼$28.67Volume3.32 million shsAverage Volume3.32 million shsMarket Capitalization$3.23 billionP/E RatioN/ADividend Yield1.63%Price Target$23.55Consensus RatingHold Company Overview Chemours Company, established in 2015 as a spin-off from E. I. du Pont de Nemours and Company, is a global chemistry organization headquartered in Wilmington, Delaware. Since its formation, Chemours has focused on delivering performance chemicals that help customers lower their carbon footprint, increase energy efficiency and conserve water. The company operates with a commitment to safety, environmental stewardship and innovation. Chemours’ principal business activities are organized into three core segments. The Titanium Technologies segment produces and markets titanium dioxide, a critical ingredient in paints, coatings, plastics, paper and other consumer goods. The Thermal & Specialized Solutions segment supplies refrigerants, cooling and heating products, as well as industrial chemicals used in mining, metals processing and refrigeration. The Advanced Performance Materials segment offers specialty fluoropolymers and fluorinated surfactants that serve high-technology applications such as semiconductor manufacturing, automotive components and electronics. With manufacturing facilities and research centers across North America, Europe, Asia Pacific and Latin America, Chemours serves a diverse international customer base spanning automotive, construction, electronics, packaging and general industrial markets. At its inception, Mark P. Vergnano was appointed chief executive officer and has overseen the company’s strategic growth and operational integration. Under its leadership team, Chemours continues to invest in process improvements, digitalization and sustainable product development to meet evolving regulatory and customer demands worldwide.AI Generated. May Contain Errors. Read More Chemours Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks72nd Percentile Overall ScoreCC MarketRank™: Chemours scored higher than 72% of companies evaluated by MarketBeat, and ranked 78th out of 181 stocks in the basic materials sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.0 / 5Analyst RatingHold Consensus RatingChemours has received a consensus rating of Hold. The company's average rating score is 2.38, and is based on no strong buy ratings, 6 buy ratings, 6 hold ratings, and 1 sell rating.Upside/DownsideThe consensus price target for Chemours is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageChemours has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Chemours' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth80.31% Earnings GrowthEarnings for Chemours are expected to grow by 80.31% in the coming year, from $1.27 to $2.29 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Chemours is -8.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Chemours is -8.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioChemours has a P/B Ratio of 14.91. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Chemours' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted5.68% of the float of Chemours has been sold short.Short Interest Ratio / Days to CoverChemours has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Chemours has recently decreased by 10.32%, indicating that investor sentiment is improving significantly. Dividend1.7 / 5Dividend StrengthWeak Dividend YieldChemours pays a meaningful dividend of 1.57%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthChemours does not have a long track record of dividend growth.Dividend SustainabilityBased on earnings estimates, Chemours will have a dividend payout ratio of 15.28% next year. This indicates that Chemours will be able to sustain or increase its dividend.Read more about Chemours' dividend. News and Social Media2.3 / 5News Sentiment-0.32 News SentimentChemours has a news sentiment score of -0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.50 average news sentiment score of Basic Materials companies.News Coverage This WeekMarketBeat has tracked 18 news articles for Chemours this week, compared to 5 articles on an average week.Search Interest9 people have searched for CC on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat Follows3 people have added Chemours to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Chemours insiders have not sold or bought any company stock.Percentage Held by Insiders0.85% of the stock of Chemours is held by insiders.Percentage Held by Institutions76.26% of the stock of Chemours is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Chemours' insider trading history. Receive CC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Chemours and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CC Stock News HeadlinesEnlightify (NYSE:ENFY) versus Chemours (NYSE:CC) Critical AnalysisMay 19 at 5:23 AM | americanbankingnews.comTrump's Manufacturing Push Is Creating Tailwinds for These 3 Stocks Under $30May 15, 2026 | 247wallst.comBefore you buy SpaceX shares, consider this alternative approachSpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceeding $1.75 trillion - potentially the largest IPO in history. But one expert says buying shares directly may not be the smartest move. There is a lesser-known way to tap into this windfall that most investors haven't considered.May 21 at 1:00 AM | Weiss Ratings (Ad)Chemours (CC) price target increased by 20.11% to 27.41May 14, 2026 | msn.comThe Chemours Company: New Industry Study, Identifies Path to Cut Cumulative Automotive Refrigerant Emissions Across Europe by ˜50% Between 2030-2050May 13, 2026 | finanznachrichten.deThe Chemours Company (NYSE:CC) Receives Average Rating of "Hold" from AnalystsMay 13, 2026 | americanbankingnews.comDo These 3 Checks Before Buying The Chemours Company (NYSE:CC) For Its Upcoming DividendMay 11, 2026 | finance.yahoo.comThe Chemours Company 2026 Q1 - Results - Earnings Call PresentationMay 7, 2026 | seekingalpha.comSee More Headlines CC Stock Analysis - Frequently Asked Questions How have CC shares performed this year? Chemours' stock was trading at $11.76 at the start of the year. Since then, CC stock has increased by 82.6% and is now trading at $21.4720. How were Chemours' earnings last quarter? The Chemours Company (NYSE:CC) issued its quarterly earnings data on Tuesday, May, 5th. The specialty chemicals company reported $0.05 earnings per share for the quarter, beating the consensus estimate of ($0.05) by $0.10. Chemours's quarterly revenue was up 1.0% on a year-over-year basis. Read the conference call transcript. Who are Chemours' major shareholders? Chemours' top institutional investors include Dimensional Fund Advisors LP (1.49%), Bank of New York Mellon Corp (1.07%), Bank of America Corp DE (0.88%) and Principal Financial Group Inc. (0.49%). Insiders that own company stock include Mark Newman, Denise Dignam, Damian Gumpel, Shane Hostetter, Matthew S Abbott, Diane I Picho and Alvenia Scarborough. View institutional ownership trends. How do I buy shares of Chemours? Shares of CC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Chemours own? Based on aggregate information from My MarketBeat watchlists, some other companies that Chemours investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), AT&T (T), Tesla (TSLA), Chevron (CVX) and JPMorgan Chase & Co. (JPM). Company Calendar Record date for 3/13 Dividend2/27/2026Ex-Dividend for 3/13 Dividend2/27/2026Dividend Payable3/13/2026Last Earnings5/05/2026Ex-Dividend for 6/16 Dividend5/15/2026Record date for 6/16 Dividend5/17/2026Today5/21/2026Dividend Payable6/16/2026Next Earnings (Estimated)8/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (4m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 CC's financial health is in the Green zone, according to TradeSmith. CC has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNYSE SectorBasic Materials Industry CHEM - DIVERSIFD Sub-IndustryChemicals Current SymbolNYSE:CC CIK1627223 Webwww.chemours.com Phone(302) 773-1000FaxN/AEmployees5,700Year Founded2015Price Target and Rating Average Price Target for Chemours$23.55 High Price Target$30.00 Low Price Target$13.00 Potential Upside/Downside+9.7%Consensus RatingHold Rating Score (0-4)2.38 Research Coverage13 Analysts Profitability EPS (Trailing Twelve Months)($2.64) Trailing P/E RatioN/A Forward P/E Ratio16.91 P/E GrowthN/ANet Income-$386 million Net Margins-6.82% Pretax Margin-5.14% Return on Equity52.49% Return on Assets1.78% Debt Debt-to-Equity Ratio18.98 Current Ratio1.82 Quick Ratio0.87 Sales & Book Value Annual Sales$5.81 billion Price / Sales0.56 Cash Flow$3.18 per share Price / Cash Flow6.76 Book Value$1.44 per share Price / Book14.91Miscellaneous Outstanding Shares150,380,000Free Float149,100,000Market Cap$3.23 billion OptionableOptionable Beta1.47 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NYSE:CC) was last updated on 5/21/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding The Chemours Company Please log in to your account or sign up in order to add this asset to your watchlist. Share Chemours With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.